A study presented at the EULAR 2024 Congress showed that treatment with nipocalimab, a neonatal Fc receptor blocker, led to significant improvement in patients with Sjögren’s disease compared to placebo at week 24. Nipocalimab targets the underlying causes of Sjögren’s disease by lowering levels of immunoglobulin G autoantibodies. The study included 163 patients, with the 15 mg/kg dose showing the most improvement in disease activity. Patients also reported improvement in symptoms like dry mouth and eyes. While adverse events were reported, they were not correlated with the treatment. Overall, nipocalimab showed promise as a potential treatment for Sjögren’s disease.
Source link
‘Proof of concept’ established for FcRn receptor blocker nipocalimab in Sjogren’s disease
